Nowell and Hungerford discovered it. A few years later, Nora Heisterkamp, M. Owen Witte, M. In the s, Brian Druker, M. Working with Nicholas Lydon, M. Druker searched through an extensive collection of compounds for one that could do just that. Remarkably, the pair identified a drug that was incredibly good at killing CML cells. In fact, it was far better than any other drug they investigated.
In , Dr. Druker and his colleagues tested imatinib in a phase 1 clinical trial partially funded by NCI. The drug caused cancer to disappear in the majority of patients with CML that was in the early, or chronic, phase of the disease. But these once-dying patients were getting out of bed, dancing, going hiking, doing yoga. Druker said in a interview with The New York Times. Subsequent clinical trials found similar results in larger groups of patients.
In addition to transforming the outcome for patients with CML, the discovery of imatinib helped establish a group of cancer drugs, called targeted therapies , that are designed to attack cancer cells with specific genetic abnormalities. Menu Contact Dictionary Search. Understanding Cancer. What Is Cancer? Cancer Statistics. Cancer Disparities. Cancer Causes and Prevention. Risk Factors. Cancer Prevention Overview. Cancer Screening Overview. Screening Tests. Diagnosis and Staging.
Questions to Ask about Your Diagnosis. Types of Cancer Treatment. Side Effects of Cancer Treatment. Clinical Trials Information. A to Z List of Cancer Drugs. Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Day-to-Day Life.
Support for Caregivers. Questions to Ask About Cancer. This proved to be the case, though the morbidity and indeed mortality associated with allogeneic stem cell transplants remained a major problem. Some of the patients who received this treatment achieved Philadelphia chromosome negativity and a small number of patients who achieved this status did not relapse when the IFN was discontinued.
Interferon was associated with modest prolongation of life when compared with the use of hydroxyurea but still in the s treatment for CML patients remained very imperfect. In the s Brian Druker in conjunction with scientists at Ciba Geigy in Basel started working on the notion that a small molecule that blocked the enzymatic action of the BCR-ABL protein might be clinical value.
The culmination of their research was the development of a phenylaminopyrimidine molecule, then called CGPB and now imatinib, that seemed to have selective action against CML cells in the laboratory. It was first used in the clinic in to treat patients with interferon-resistant CML in chronic phase. Soon thereafter it was used to treat previously untreated CML patient. The clinical picture has been further improved by the introduction of more powerful agents that act in a manner similar to imatinib, namely dasatinib, nilotinib and bosutinib, though the last drug is not yet approved for use outside the context of a clinical study.
Viewed over a period of 50 years, the treatment of CML must be regarded as a remarkable success. In , Ernst Neumann observed that leukemia cells originated in the bone marrow. The next decades saw the differentiation into myeloid versus lymphoid and acute versus chronic leukemias. A real quantum leap, however, was the discovery by Philadelphia cytogeneticists Peter Nowel and David Hungerford of an abnormally small G-group chromosome that we now call the Philadelphia chromosome Ph.
This was a seminal step, as it unequivocally proved that cancer was a problem of DNA. Thirteen years later Janet Rowley recognized that Ph was the product of a reciprocal translocation between chromosomes 9 and A faithful murine disease model was established in Therapy developed slowly.
In , Heinrich Lissauer described the use of arsenic in two patients with leukemia, nothing too novel in view of the fact that the use of arsenic for cancer therapy had been described in the Indian Ramayana more than years earlier. ScienceWatch Bioethics in Genetics. Genetic Inequality: Human Genetic Engineering. Questionable Prognostic Value of Genetic Testing. Human Subjects and Diagnostic Genetic Testing.
Prenatal Screen Detects Fetal Abnormalities. Legislative Landmarks of Forensics: California v. Greenwood and Shed DNA. Calculation of Complex Disease Risk.
Gene Therapy. Personalized Medicine: Hope or Hype? Pharmacogenetics, Personalized Medicine, and Race. Pharmacogenomics and Personalized Medicine. Medical Careers: Genetic Screening and Diagnostics.
Pray, Ph. Citation: Pray, L. Nature Education 1 1 How do scientists develop new treatments for disease? With Gleevec, a remarkable cancer drug, the approach was to target the disease at the cellular and subcellular level.
Aa Aa Aa. Some say it's a miracle drug. Others call it a silver bullet. Gleevec, also marketed internationally as Glivec and sometimes referred to by its chemical name imatinib, entered the medical world with a bang. This medication was initially approved for use by the U.
Food and Drug Administration FDA in for the treatment of chronic myelogenous leukemia CML , a rare form of cancer that affects certain types of white blood cells. Since its initial approval, Gleevec has also been approved for use in patients with several types of gastrointestinal tumors. Currently, scientists continue to study the drug's effectiveness not only in various cancers, but also in other diseases, such as stroke Su et al.
But just how effective is Gleevec, especially when it comes to CML, and what is its mechanism of action? Gleevec Statistics. As Nowell recounts: I knew nothing about cytogenetics at this time but felt that the chromosomal preparations of the leukemic cells warranted investigation for any abnormalities.
Details of the Philadelphia Chromosome Begin to Emerge. Figure 1: The Philadelphia chromosome. Discovered in , the diagnostic karyotypic abnormality for chronic myelogenous leukemia is shown in this picture of the banded chromosomes 9 and Shown is the result of the reciprocal translocation of 22q to the lower arm of 9 and 9q c-abl to a specific breakpoint cluster region [bcr] of chromosome 22 indicated by the arrows.
Nowell Courtesy of Peter C. All rights reserved. References and Recommended Reading Cameron, D. Cell 36 , 93—99 Heisterkamp, N. Journal of Clinical Investigation , — Rowley, J. Article History Close. Share Cancel. Revoke Cancel. Keywords Keywords for this Article. Save Cancel. Flag Inappropriate The Content is: Objectionable. Flag Content Cancel.
0コメント